Panaxynol improves crypt and mucosal architecture, suppresses colitis-enriched microbes, and alters the immune response to mitigate colitis
American Journal of Physiology-Gastrointestinal and Liver Physiology · 01.05.2024 · 326 (5) · G591-G606
DOI: 10.1152/ajpgi.00004.2024 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Physiology-Gastrointestinal and Liver Physiology, erschienen am 01.05.2024. Verfasst von Brooke M Bullard und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Microbiology, and Immunology, School of Medicine, University of South Carolina, Columbia, South Carolina, United States. Hauptthemen laut MEDLINE: Intestinal Mucosa, Mice, Inbred C57BL, Gastrointestinal Microbiome, Dextran Sulfate. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, HHS | NIH | National Cancer Institute (NCI).
Abstract (Originalsprache)
In the current study, we report that panaxynol ameliorates chemically induced murine colitis by improving colonic crypt and mucosal architecture, suppressing colitis-enriched microbes, reducing macrophages, and promoting the differentiation of regulatory T-cells in the colonic lamina propria. This study suggests that this novel natural compound may serve as a safe and effective treatment option for colitis patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Microbiology, and Immunology, School of Medicine, University of South Carolina, Columbia, South Carolina, United States.
- Department of Nutritional Sciences, College of Agricultural and Life Sciences, University of Wisconsin-Madison, Madison, Wisconsin, United States.
- Department of Cell Biology and Anatomy, School of Medicine, University of South Carolina, Columbia, South Carolina, United States.
- Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, South Carolina, United States.
ORCID-Profile: Brooke M Bullard, Sierra J McDonald, Brandon N VanderVeen, Joseph F Pierre, Ioulia Chatzistamou, E Angela Murphy
Förderung
- NCI NIH HHS
- HHS | NIH | National Cancer Institute (NCI)
Zitieren
APA
Bullard, B. M., McDonald, S. J., Cardaci, T. D., VanderVeen, B. N., Mohammed, A. D., Kubinak, J. L., Pierre, J. F., Chatzistamou, I., Fan, D., Hofseth, L. J., & Murphy, E. A. (2024). Panaxynol improves crypt and mucosal architecture, suppresses colitis-enriched microbes, and alters the immune response to mitigate colitis. American Journal of Physiology-Gastrointestinal and Liver Physiology, 326(5), G591-G606. https://doi.org/10.1152/ajpgi.00004.2024
Vancouver
Bullard BM, McDonald SJ, Cardaci TD, VanderVeen BN, Mohammed AD, Kubinak JL, et al. Panaxynol improves crypt and mucosal architecture, suppresses colitis-enriched microbes, and alters the immune response to mitigate colitis. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2024;326(5):G591-G606. doi:10.1152/ajpgi.00004.2024
BibTeX
@article{Bullard2024,
author = {Bullard, Brooke M and McDonald, Sierra J and Cardaci, Thomas D and VanderVeen, Brandon N and Mohammed, Ahmed D and Kubinak, Jason L and Pierre, Joseph F and Chatzistamou, Ioulia and Fan, Daping and Hofseth, Lorne J and Murphy, E Angela},
title = {Panaxynol improves crypt and mucosal architecture, suppresses colitis-enriched microbes, and alters the immune response to mitigate colitis},
journal = {American Journal of Physiology-Gastrointestinal and Liver Physiology},
year = {2024},
volume = {326},
number = {5},
pages = {G591--G606},
doi = {10.1152/ajpgi.00004.2024}
}
EUVIMED